COVID information

In the context of the current global health crisis caused by COVID-19, Aromics remains open. It also reports that since the beginning of the COVID-19 pandemic, the company is executing the necessary contingency plans to guarantee the health and safety of its employees, as well as to ensure business continuity, and to fulfill its responsibility to continue developing experimental drugs for serious illnesses with unmet medical needs.